2019 Pipeline Review on Iron Deficiency Anemia (H1) - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Apr 16, 2019--The “Iron Deficiency Anemia - Pipeline Review, H1 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Iron Deficiency Anemia - Pipeline Review, H1 2019 provides comprehensive information on the therapeutics under development for Iron Deficiency Anemia (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Iron Deficiency Anemia (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Iron Deficiency Anemia and features dormant and discontinued projects.
The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 3, 3, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.
Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
- The pipeline guide provides a snapshot of the global therapeutic landscape of Iron Deficiency Anemia (Hematological Disorders).
- The pipeline guide reviews pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Iron Deficiency Anemia (Hematological Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Iron Deficiency Anemia (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Iron Deficiency Anemia (Hematological Disorders)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Iron Deficiency Anemia (Hematological Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Iron Deficiency Anemia (Hematological Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Featured News & Press Releases
- Jan 29, 2019: Positive results of long-term phase of AEGIS-CKD study further demonstrate the benefits of Feraccru
- Jan 24, 2019: Shield Therapeutics: Business and trading update
- Dec 13, 2018: Shield Therapeutics announces the US new drug application PDUFA date for Feraccru
- Dec 10, 2018: Rockwell Medical appoints new Vice President, Operations
- Dec 06, 2018: Clinical trial sheds new light on potential risk associated with intravenous iron treatment
- Dec 05, 2018: Shield Therapeutics notes UK launch of Feraccru by Norgine
- Dec 04, 2018: New study demonstrates significant difference between Iron Isomaltoside and Ferric Carboxymaltose on hypophosphatemic effects in a controlled, randomized clinical investigation
- Dec 03, 2018: Shield Therapeutics announces the new drug application for Feraccru has been accepted for filing and review by the FDA
- Oct 12, 2018: Rockwell Medical provides update on IV Triferic
- Oct 01, 2018: Shield Therapeutics announces submission of a New Drug Application (NDA) for Feraccru for the treatment of iron deficiency with the US Food and Drug Administration (FDA)
- Sep 13, 2018: Shield reports completion of recruitment to AEGIS Head to Head Study (AEGIS-H2H) comparing Feraccru with ferric carboxymaltose
- Sep 06, 2018: Monoferric receives marketing approval from Health Canada
- Jun 28, 2018: Shield Reports Recently Presented Supportive Data from Real-world Clinical use of Feraccru (Ferric Maltol)
- Jun 14, 2018: Shield reports positive top-line results from its AEGIS-PAED PK Paediatric Phase I Pharmacokinetics study of Feraccru (Ferric Maltol) in subjects with iron deficiency
- May 02, 2018: Rockwell Medical Announces Triferic Presentations at the 2018 International Congress on Peritoneal Dialysis
- Akebia Therapeutics Inc.
- Iron4u ApS
- Novartis AG
- Panion & BF Biotech Inc.
- Pharmacosmos AS
- Pieris Pharmaceuticals Inc.
- Rockwell Medical Inc.
- Shield Therapeutics PLC
- Vifor Pharma Ltd.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m5598
View source version on businesswire.com:https://www.businesswire.com/news/home/20190416005664/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Hematological Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 04/16/2019 09:35 AM/DISC: 04/16/2019 09:35 AM